Based on the news about the stock in the past five trading days, please predict the rise or fall of the stock in the next trading day. If the stock is predicted to rise in the next trading day, please output [Rise], if the stock is predicted to fall in the next trading day, please output [Decrease].

Date:2018-03-01, Stock:LLY, The news for the past five days is as follows:
2018-02-22: NEWS1: Eli Lilly’s New Product Portfolio in 4Q17.NEWS2: A Look at Eli Lilly’s Neuroscience Portfolio in 4Q17.NEWS3: Eli Lilly’s Oncology Portfolio in 4Q17.NEWS4: How Eli Lilly’s Cardiovascular Portfolio Performed in 4Q17.NEWS5: Comparing Eli Lilly’s Business Segments in 4Q17.NEWS6: Eli Lilly’s Human Pharmaceutical Portfolio in 4Q17.NEWS7: A Look at Eli Lilly’s 4Q17 Revenue.NEWS8: United Therapeutics (UTHR) Q4 Earnings Decline on High Costs.NEWS9: United Therapeutics (UTHR) Q4 Earnings Decline on High Costs.
2018-02-23: NEWS1: A Look at Vanda Pharmaceuticals’ Product Portfolio.NEWS2: Endo, Glaxo to Settle Suits Over Testosterone Drug.NEWS3: Analysts’ Post-4Q17 Recommendations for Eli Lilly.NEWS4: Comparing Eli Lilly’s Post-4Q17 Valuation.NEWS5: Today’s Research Reports on Trending Tickers: InspireMD and Eli Lilly and Company.NEWS6: How Eli Lilly’s Animal Health Segment Performed in 4Q17.
2018-02-26: NEWS1: Lilly breast cancer drug wins expanded U.S. approval.NEWS2: Lilly Receives Additional FDA Approval for VerzenioTM (abemaciclib), as Initial Treatment for Advanced Breast Cancer.NEWS3: Eli Lilly Announces Additional FDA Approval For Verzenio - Quick Facts.NEWS4: Eli Lilly Announces Additional FDA Approval For Verzenio - Quick Facts.NEWS5: Radius Health (RDUS) to Disappoint Investors in Q4 Earnings?.NEWS6: Radius Health (RDUS) to Disappoint Investors in Q4 Earnings?.NEWS7: Health Care Sector Update for 02/26/2018: ACHN, OBSV, EGRX, LLY, CNC.NEWS8: Health Care Sector Update for 02/26/2018: ACHN, OBSV, EGRX, LLY, CNC.NEWS9: Johnson & Johnson’s Neuroscience Segment in 2017.NEWS10: New Data Show Lilly's Trulicity® (dulaglutide) in Combination with an SGLT-2 Inhibitor Improves Blood Sugar Control in People with Type 2 Diabetes.NEWS11: Eli Lilly Reports New Data From Trulicity Phase 3b Study - Quick Facts.NEWS12: Eli Lilly Reports New Data From Trulicity Phase 3b Study - Quick Facts.
2018-02-27: NEWS1: Eli Lilly Needs to Prove It Can Overcome Resistance Above $82.NEWS2: Lilly's Verzenio Wins FDA Nod for First Line Breast Cancer.NEWS3: Lilly's Verzenio Wins FDA Nod for First Line Breast Cancer.NEWS4: Lilly&apos;s Verzenio Wins FDA Nod for First Line Breast Cancer.NEWS5: Benzinga Pro's 5 Stocks To Watch Today.
2018-02-28: nan

Answer: Decrease